Senesco and Rahan Meristem Report Positive Disease Resistance Results from Banana Field Trials.

NEW BRUNSWICK, NJ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) and Rahan Meristem, Ltd. ("Rahan") announced today that field trials of Senesco/Rahan banana plants have shown increased tolerance to the Black Sigatoka disease, as measured on an index of tolerance widely used in the industry for this disease.

Black Sigatoka, which is also referred to as Black Leaf Streak Disease ("BLSD"), is the predominant leaf spot disease of banana and is known to cause significant reductions in leaf area, yield losses of 50% or more, and premature ripening, a serious defect in exported fruit.

These field trial data corroborate the Company's earlier findings that its proprietary Factor 5A technology confers resistance to fungal pathogens by preventing premature plant cell death. In addition to these banana disease tolerance data, Senesco and Rahan have previously shown both an increase in banana fruit shelf life and increase in growth rates of banana plants in field trials.

Eli Khayat, the Scientific Director of Rahan stated, "These data are encouraging and may lead to the achievement of Rahan's major R&D objective -- developing a 'Cavendish' banana with resistance to BLSD."

"Black Sigatoka is a primary focus of research in the banana industry," stated Bruce Galton, President and CEO of Senesco. "We believe that our technology can benefit the banana industry in a variety of ways. We are now working with our partners at Rahan to combine disease tolerance and extended shelf life into one product, which we hope will move towards our goal of commercialization."

About Rahan Meristem

Rahan Meristem is considered one of the most outstanding companies for the selection, breeding and production of vegetatively propagated plants. Working to improve plant varieties with cutting edge molecular biology techniques, Rahan has developed protocols for over 200 plant genera over the past 20 years. Rahan's tissue culture lab is among the most advanced in the world and is the nucleus of a highly integrated R&D network of acclimatization houses, nurseries and experimental plots.

About Senesco Technologies, Inc.

Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates cell life. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has undertaken preclinical research in certain areas of human health.

Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at universities and research centers throughout North America.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.